The therapeutic potential of AMV564, a novel bispecific bivalent (2x2) T-cell engager, for the treatment of CD33-expressing hematologic malignancies

被引：1

作者：

Han, Tae H. ^{[1
]}

Guenot, Jeanmarie ^{[1
]}

Denney, William S. ^{[2
]}

Feldman, Eric J. ^{[1
]}

机构：

[1] Amphivena Therapeut, San Francisco, CA USA

[2] Human Predict, Cambridge, MA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-5548

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5548

引用

页数：2

共 19 条

[1] AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia
Eissenberg, Linda G.
Ritchey, Julie
Rettig, Michael P.
Fox, Judith A.
Guenot, Jeanmarie
DiPersio, John F.
BLOOD, 2018, 132
[2] AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells
Eckard, Sterling
Gehrs, Leah
Smith, Victoria
Guenot, Jeanmarie
DiPersio, John
Wei, Sheng
Rettig, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[3] Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
Cheng, Pingyan
Chen, Xianghong
Dalton, Robert
Calescibetta, Alexandra
So, Tina
Gilvary, Danielle
Ward, Grace
Smith, Victoria
Eckard, Sterling
Fox, Judith A.
Guenot, Jeanmarie
Markowitz, Joseph
Cleveland, John L.
Wright, Kenneth L.
List, Alan F.
Wei, Sheng
Eksioglu, Erika A.
MOLECULAR THERAPY, 2022, 30 (06) : 2315 - 2326
[4] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Roboz, Gail J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Lee, Sangmin
Rettig, Michael P.
Han, Tae H.
Guenot, Jeanmarie
Feldman, Eric J.
DiPersio, John F.
BLOOD, 2018, 132
[5] Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager
Eissenberg, Linda G.
Ritchey, Julie K.
Rettig, Michael P.
Patel, Dilan A.
Vij, Kiran
Gao, Feng
Smith, Victoria
Han, Tae H.
Dipersio, John F.
PLOS ONE, 2024, 19 (05):
[6] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Cortes, Jorge E.
Altman, Jessica K.
Long, Meixiao
Oehler, Vivian G.
Gojo, Ivana
Guenot, Jeanmarie
Chun, Patrick
Roboz, Gail J.
BLOOD, 2019, 134
[7] AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients
Smith, Victoria
Eckard, Sterling
Rettig, Michael P.
Gehrs, Leah N.
Guenot, Jeanmarie
Wei, Sheng
DiPersio, John F.
CANCER RESEARCH, 2020, 80 (16)
[8] Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro
Cheng, Pingyan
Eksioglu, Erika
Chen, Xianghong
Wei, Max
Guenot, Jeanmarie
Fox, Judy
List, Alan F.
Wei, Sheng
BLOOD, 2017, 130
[9] ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
Chervin, Adam S.
Stone, Jennifer D.
Konieczna, Iwona
Calabrese, Kelly M.
Wang, Ningyan
Haribhai, Dipica
Dong, Feng
White, Michael K.
Rodriguez, Luis E.
Bukofzer, Gail T.
Ellis, Paul A.
Cosgrove, Cormac
Hecquet, Claudie
Clarin, Jerry D.
Palma, Joann P.
Reilly, Edward B.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (08) : 903 - 912
[10] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
Cugnetti, Ana Paula
Liu, Haizhen
McNeeley, Patricia
Wheeler, Christina
Lucas, Matthew
Xing, Charles
Joyner, Solmarie
Johnson, Kyrie
Woodard, Kathryn
Zhou, Wei
Chang, Cathy
Frey, Gerhard
Boyle, William J.
Short, Jay M.
CANCER RESEARCH, 2023, 83 (07)

← 1 2 →